4974.T
Takara Bio Inc.
4974.T
(3.2)1.078,00 JPY
0.1% ROA
0.1% ROE
1116.48x PER
127.279.712.000,00 JPY
0% DER
1.61% Yield
0.27% NPM
Takara Bio Inc. Stock Analysis
Takara Bio Inc. Fundamental Analysis
Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.
| # | Analysis | Rating |
|---|---|---|
| 1 |
ROA
This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors. |
|
| 2 |
DER
The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors. |
|
| 3 |
Assets Growth
With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance. |
|
| 4 |
Dividend Growth
With a history of consistent dividend increases over the last five years, the company has proven to be a reliable choice for investors seeking steady income. |
|
| 5 |
ROE
ROE in an average range (14.84%) suggests satisfactory profitability and decent utilization of shareholders' equity. |
|
| 6 |
PBV
The stock's PBV ratio (1.47x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns. |
|
| 7 |
Graham Number
The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity. |
|
| 8 |
Dividend
The company's history of regular dividend distributions in the last three years showcases its ability to generate reliable income for shareholders. |
|
| 9 |
Buffet Intrinsic Value
Warren Buffett's formula suggests that the company's stock is undervalued (9.329), making it an appealing investment prospect with its intrinsic value surpassing the current market price. |
|
| 10 |
Revenue Growth
Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice. |
|
| 11 |
Net Profit Growth
Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option. |
Takara Bio Inc. Technical Analysis
Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.
| # | Analysis | Recommendation |
|---|---|---|
| 1 | Awesome Oscillator | Buy |
| 2 | MACD | Buy |
| 3 | RSI | Hold |
| 4 | Stoch RSI | Sell |
Takara Bio Inc. Price Chart
Financial Statements
Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.
Income Statements
An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.
Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.
| Year | Revenue | Growth |
|---|---|---|
| 2004 | 13.685.000.000 | |
| 2005 | 16.534.000.000 | 17.23% |
| 2006 | 20.982.000.000 | 21.2% |
| 2007 | 20.278.000.000 | -3.47% |
| 2008 | 18.913.000.000 | -7.22% |
| 2009 | 19.325.000.000 | 2.13% |
| 2010 | 18.737.000.000 | -3.14% |
| 2011 | 19.578.000.000 | 4.3% |
| 2012 | 20.564.000.000 | 4.79% |
| 2013 | 23.905.000.000 | 13.98% |
| 2014 | 25.969.000.000 | 7.95% |
| 2015 | 29.729.000.000 | 12.65% |
| 2016 | 29.375.000.000 | -1.21% |
| 2017 | 32.312.000.000 | 9.09% |
| 2018 | 35.841.000.000 | 9.85% |
| 2019 | 34.565.000.000 | -3.69% |
| 2020 | 46.086.000.000 | 25% |
| 2021 | 67.699.000.000 | 31.93% |
| 2022 | 78.142.000.000 | 13.36% |
| 2023 | 39.760.000.000 | -96.53% |
| 2023 | 43.505.000.000 | 8.61% |
| 2024 | 33.972.000.000 | -28.06% |
Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.
| Year | Research and Development Expenses | Growth |
|---|---|---|
| 2004 | 2.987.000.000 | |
| 2005 | 3.121.000.000 | 4.29% |
| 2006 | 3.239.000.000 | 3.64% |
| 2007 | 3.296.000.000 | 1.73% |
| 2008 | 2.976.000.000 | -10.75% |
| 2009 | 3.294.000.000 | 9.65% |
| 2010 | 2.692.000.000 | -22.36% |
| 2011 | 2.658.000.000 | -1.28% |
| 2012 | 2.715.000.000 | 2.1% |
| 2013 | 3.026.000.000 | 10.28% |
| 2014 | 3.401.000.000 | 11.03% |
| 2015 | 4.275.000.000 | 20.44% |
| 2016 | 4.101.000.000 | -4.24% |
| 2017 | 4.653.000.000 | 11.86% |
| 2018 | 4.337.000.000 | -7.29% |
| 2019 | 3.869.000.000 | -12.1% |
| 2020 | 5.545.000.000 | 30.23% |
| 2021 | 6.109.000.000 | 9.23% |
| 2022 | 8.575.000.000 | 28.76% |
| 2023 | 8.004.000.000 | -7.13% |
| 2023 | 6.873.000.000 | -16.46% |
| 2024 | 6.824.000.000 | -0.72% |
General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.
| Year | General and Administrative Expenses | Growth |
|---|---|---|
| 2004 | 0 | |
| 2005 | 0 | 0% |
| 2006 | 0 | 0% |
| 2007 | 95.000.000 | 100% |
| 2008 | 102.000.000 | 6.86% |
| 2009 | 112.000.000 | 8.93% |
| 2010 | 72.000.000 | -55.56% |
| 2011 | 68.000.000 | -5.88% |
| 2012 | 0 | 0% |
| 2013 | 0 | 0% |
| 2014 | 0 | 0% |
| 2015 | 0 | 0% |
| 2016 | 0 | 0% |
| 2017 | 0 | 0% |
| 2018 | 0 | 0% |
| 2019 | 0 | 0% |
| 2020 | 0 | 0% |
| 2021 | 0 | 0% |
| 2022 | 0 | 0% |
| 2023 | 0 | 0% |
| 2023 | 0 | 0% |
| 2024 | 0 | 0% |
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.
| Year | EBITDA | Growth |
|---|---|---|
| 2004 | 2.848.000.000 | |
| 2005 | 4.300.000.000 | 33.77% |
| 2006 | 5.749.000.000 | 25.2% |
| 2007 | 6.116.000.000 | 6% |
| 2008 | 5.766.000.000 | -6.07% |
| 2009 | 5.932.000.000 | 2.8% |
| 2010 | 6.030.000.000 | 1.63% |
| 2011 | 6.602.000.000 | 8.66% |
| 2012 | 3.482.000.000 | -89.6% |
| 2013 | 3.714.000.000 | 6.25% |
| 2014 | 4.455.000.000 | 16.63% |
| 2015 | 5.369.000.000 | 17.02% |
| 2016 | 5.629.000.000 | 4.62% |
| 2017 | 7.098.000.000 | 20.7% |
| 2018 | 9.683.000.000 | 26.7% |
| 2019 | 9.879.000.000 | 1.98% |
| 2020 | 17.968.000.000 | 45.02% |
| 2021 | 32.629.000.000 | 44.93% |
| 2022 | 25.441.000.000 | -28.25% |
| 2023 | 9.452.000.000 | -169.16% |
| 2023 | 8.024.000.000 | -17.8% |
| 2024 | -1.984.000.000 | 504.44% |
Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.
| Year | Gross Profit | Growth |
|---|---|---|
| 2004 | 6.368.000.000 | |
| 2005 | 7.159.000.000 | 11.05% |
| 2006 | 9.822.000.000 | 27.11% |
| 2007 | 10.223.000.000 | 3.92% |
| 2008 | 9.940.000.000 | -2.85% |
| 2009 | 10.039.000.000 | 0.99% |
| 2010 | 9.879.000.000 | -1.62% |
| 2011 | 10.384.000.000 | 4.86% |
| 2012 | 11.024.000.000 | 5.81% |
| 2013 | 12.574.000.000 | 12.33% |
| 2014 | 13.827.000.000 | 9.06% |
| 2015 | 16.324.000.000 | 15.3% |
| 2016 | 16.953.000.000 | 3.71% |
| 2017 | 18.655.000.000 | 9.12% |
| 2018 | 20.686.000.000 | 9.82% |
| 2019 | 21.106.000.000 | 1.99% |
| 2020 | 31.872.000.000 | 33.78% |
| 2021 | 49.211.000.000 | 35.23% |
| 2022 | 44.765.000.000 | -9.93% |
| 2023 | 27.404.000.000 | -63.35% |
| 2023 | 25.457.000.000 | -7.65% |
| 2024 | 17.416.000.000 | -46.17% |
Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.
| Year | Net Profit | Growth |
|---|---|---|
| 2004 | -1.282.000.000 | |
| 2005 | -1.058.000.000 | -21.17% |
| 2006 | 320.000.000 | 430.63% |
| 2007 | 679.000.000 | 52.87% |
| 2008 | 642.000.000 | -5.76% |
| 2009 | 591.000.000 | -8.63% |
| 2010 | 605.000.000 | 2.31% |
| 2011 | 1.023.000.000 | 40.86% |
| 2012 | 1.462.000.000 | 30.03% |
| 2013 | 1.470.000.000 | 0.54% |
| 2014 | 963.000.000 | -52.65% |
| 2015 | 1.334.000.000 | 27.81% |
| 2016 | 1.352.000.000 | 1.33% |
| 2017 | 2.335.000.000 | 42.1% |
| 2018 | 3.657.000.000 | 36.15% |
| 2019 | 3.819.000.000 | 4.24% |
| 2020 | 9.547.000.000 | 60% |
| 2021 | 19.849.000.000 | 51.9% |
| 2022 | 16.012.000.000 | -23.96% |
| 2023 | 3.060.000.000 | -423.27% |
| 2023 | 1.480.000.000 | -106.76% |
| 2024 | -4.188.000.000 | 135.34% |
EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.
| Year | Earning per Share (EPS) | Growth |
|---|---|---|
| 2004 | -14 | |
| 2005 | -10 | -44.44% |
| 2006 | 3 | 550% |
| 2007 | 6 | 66.67% |
| 2008 | 6 | -20% |
| 2009 | 5 | 0% |
| 2010 | 5 | 0% |
| 2011 | 9 | 44.44% |
| 2012 | 13 | 25% |
| 2013 | 13 | 0% |
| 2014 | 8 | -50% |
| 2015 | 11 | 27.27% |
| 2016 | 11 | 0% |
| 2017 | 19 | 42.11% |
| 2018 | 30 | 36.67% |
| 2019 | 32 | 3.23% |
| 2020 | 79 | 60.76% |
| 2021 | 165 | 51.83% |
| 2022 | 133 | -24.24% |
| 2023 | 0 | 0% |
| 2023 | 12 | 100% |
| 2024 | -35 | 135.29% |
Cashflow Statements
Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.
Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.
| Year | Free Cashflow | Growth |
|---|---|---|
| 2004 | -980.000.000 | |
| 2005 | -878.000.000 | -11.62% |
| 2006 | 2.239.000.000 | 139.21% |
| 2007 | 185.000.000 | -1110.27% |
| 2008 | 1.212.000.000 | 84.74% |
| 2009 | 1.828.000.000 | 33.7% |
| 2010 | 912.000.000 | -100.44% |
| 2011 | 1.355.000.000 | 32.69% |
| 2012 | -277.000.000 | 589.17% |
| 2013 | -3.462.000.000 | 92% |
| 2014 | -1.333.000.000 | -159.71% |
| 2015 | 647.000.000 | 306.03% |
| 2016 | 2.067.000.000 | 68.7% |
| 2017 | 2.343.000.000 | 11.78% |
| 2018 | -299.000.000 | 883.61% |
| 2019 | 2.287.000.000 | 113.07% |
| 2020 | 5.098.000.000 | 55.14% |
| 2021 | -5.554.000.000 | 191.79% |
| 2022 | 31.015.000.000 | 117.91% |
| 2023 | -8.253.000.000 | 475.8% |
| 2023 | -11.067.000.000 | 25.43% |
| 2024 | 3.750.000.000 | 395.12% |
Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.
| Year | Operating Cashflow | Growth |
|---|---|---|
| 2004 | 1.155.000.000 | |
| 2005 | 626.000.000 | -84.5% |
| 2006 | 3.128.000.000 | 79.99% |
| 2007 | 2.018.000.000 | -55% |
| 2008 | 2.265.000.000 | 10.91% |
| 2009 | 3.174.000.000 | 28.64% |
| 2010 | 2.093.000.000 | -51.65% |
| 2011 | 2.366.000.000 | 11.54% |
| 2012 | 2.226.000.000 | -6.29% |
| 2013 | 2.251.000.000 | 1.11% |
| 2014 | 3.558.000.000 | 36.73% |
| 2015 | 3.021.000.000 | -17.78% |
| 2016 | 3.584.000.000 | 15.71% |
| 2017 | 3.935.000.000 | 8.92% |
| 2018 | 5.783.000.000 | 31.96% |
| 2019 | 6.339.000.000 | 8.77% |
| 2020 | 13.943.000.000 | 54.54% |
| 2021 | 6.985.000.000 | -99.61% |
| 2022 | 36.897.000.000 | 81.07% |
| 2023 | 1.768.000.000 | -1986.93% |
| 2023 | 1.711.000.000 | -3.33% |
| 2024 | 4.534.000.000 | 62.26% |
Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.
| Year | Capital Expenditure | Growth |
|---|---|---|
| 2004 | 2.135.000.000 | |
| 2005 | 1.504.000.000 | -41.95% |
| 2006 | 889.000.000 | -69.18% |
| 2007 | 1.833.000.000 | 51.5% |
| 2008 | 1.053.000.000 | -74.07% |
| 2009 | 1.346.000.000 | 21.77% |
| 2010 | 1.181.000.000 | -13.97% |
| 2011 | 1.011.000.000 | -16.82% |
| 2012 | 2.503.000.000 | 59.61% |
| 2013 | 5.713.000.000 | 56.19% |
| 2014 | 4.891.000.000 | -16.81% |
| 2015 | 2.374.000.000 | -106.02% |
| 2016 | 1.517.000.000 | -56.49% |
| 2017 | 1.592.000.000 | 4.71% |
| 2018 | 6.082.000.000 | 73.82% |
| 2019 | 4.052.000.000 | -50.1% |
| 2020 | 8.845.000.000 | 54.19% |
| 2021 | 12.539.000.000 | 29.46% |
| 2022 | 5.882.000.000 | -113.18% |
| 2023 | 10.021.000.000 | 41.3% |
| 2023 | 12.778.000.000 | 21.58% |
| 2024 | 784.000.000 | -1529.85% |
Balance Sheet
Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.
Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.
| Year | Equity | Growth |
|---|---|---|
| 2004 | 31.941.000.000 | |
| 2005 | 37.306.000.000 | 14.38% |
| 2006 | 38.611.000.000 | 3.38% |
| 2007 | 39.108.000.000 | 1.27% |
| 2008 | 37.149.000.000 | -5.27% |
| 2009 | 37.799.000.000 | 1.72% |
| 2010 | 37.620.000.000 | -0.48% |
| 2011 | 38.413.000.000 | 2.06% |
| 2012 | 41.463.000.000 | 7.36% |
| 2013 | 57.124.000.000 | 27.42% |
| 2014 | 59.640.000.000 | 4.22% |
| 2015 | 60.107.000.000 | 0.78% |
| 2016 | 59.983.000.000 | -0.21% |
| 2017 | 61.956.000.000 | 3.18% |
| 2018 | 64.093.000.000 | 3.33% |
| 2019 | 66.589.000.000 | 3.75% |
| 2020 | 74.300.000.000 | 10.38% |
| 2021 | 96.062.000.000 | 22.65% |
| 2022 | 112.452.000.000 | 14.58% |
| 2023 | 112.128.000.000 | -0.29% |
| 2023 | 111.784.000.000 | -0.31% |
| 2024 | 111.516.000.000 | -0.24% |
Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.
| Year | Assets | Growth |
|---|---|---|
| 2004 | 37.427.000.000 | |
| 2005 | 44.443.000.000 | 15.79% |
| 2006 | 45.539.000.000 | 2.41% |
| 2007 | 45.289.000.000 | -0.55% |
| 2008 | 43.117.000.000 | -5.04% |
| 2009 | 43.651.000.000 | 1.22% |
| 2010 | 42.594.000.000 | -2.48% |
| 2011 | 44.032.000.000 | 3.27% |
| 2012 | 46.649.000.000 | 5.61% |
| 2013 | 62.500.000.000 | 25.36% |
| 2014 | 66.425.000.000 | 5.91% |
| 2015 | 66.591.000.000 | 0.25% |
| 2016 | 67.143.000.000 | 0.82% |
| 2017 | 68.854.000.000 | 2.48% |
| 2018 | 71.040.000.000 | 3.08% |
| 2019 | 75.009.000.000 | 5.29% |
| 2020 | 89.750.000.000 | 16.42% |
| 2021 | 115.712.000.000 | 22.44% |
| 2022 | 129.202.000.000 | 10.44% |
| 2023 | 123.283.000.000 | -4.8% |
| 2023 | 123.207.000.000 | -0.06% |
| 2024 | 121.752.000.000 | -1.2% |
Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.
| Year | Liabilities | Growth |
|---|---|---|
| 2004 | 5.486.000.000 | |
| 2005 | 7.137.000.000 | 23.13% |
| 2006 | 6.928.000.000 | -3.02% |
| 2007 | 6.181.000.000 | -12.09% |
| 2008 | 5.968.000.000 | -3.57% |
| 2009 | 5.852.000.000 | -1.98% |
| 2010 | 4.974.000.000 | -17.65% |
| 2011 | 5.619.000.000 | 11.48% |
| 2012 | 5.186.000.000 | -8.35% |
| 2013 | 5.376.000.000 | 3.53% |
| 2014 | 6.785.000.000 | 20.77% |
| 2015 | 6.484.000.000 | -4.64% |
| 2016 | 7.160.000.000 | 9.44% |
| 2017 | 6.898.000.000 | -3.8% |
| 2018 | 6.947.000.000 | 0.71% |
| 2019 | 8.420.000.000 | 17.49% |
| 2020 | 15.450.000.000 | 45.5% |
| 2021 | 19.650.000.000 | 21.37% |
| 2022 | 16.750.000.000 | -17.31% |
| 2023 | 11.155.000.000 | -50.16% |
| 2023 | 11.420.000.000 | 2.32% |
| 2024 | 10.235.000.000 | -11.58% |
Takara Bio Inc. Financial Ratio (TTM)
Valuation Metrics
- Revenue per Share
- 355.62
- Net Income per Share
- 0.95
- Price to Earning Ratio
- 1116.48x
- Price To Sales Ratio
- 2.97x
- POCF Ratio
- 21.48
- PFCF Ratio
- -20.44
- Price to Book Ratio
- 1.14
- EV to Sales
- 2.09
- EV Over EBITDA
- 14.75
- EV to Operating CashFlow
- 15.07
- EV to FreeCashFlow
- -14.34
- Earnings Yield
- 0
- FreeCashFlow Yield
- -0.05
- Market Cap
- 127,28 Bil.
- Enterprise Value
- 89,31 Bil.
- Graham Number
- 140.26
- Graham NetNet
- 329.93
Income Statement Metrics
- Net Income per Share
- 0.95
- Income Quality
- 21.63
- ROE
- 0
- Return On Assets
- 0
- Return On Capital Employed
- 0.01
- Net Income per EBT
- 0.14
- EBT Per Ebit
- 0.89
- Ebit per Revenue
- 0.02
- Effective Tax Rate
- 0.83
Margins
- Sales, General, & Administrative to Revenue
- 0
- Research & Developement to Revenue
- 0.18
- Stock Based Compensation to Revenue
- 0
- Gross Profit Margin
- 0.58
- Operating Profit Margin
- 0.02
- Pretax Profit Margin
- 0.02
- Net Profit Margin
- 0
Dividends
- Dividend Yield
- 0.02
- Dividend Yield %
- 1.61
- Payout Ratio
- 18.87
- Dividend Per Share
- 17
Operating Metrics
- Operating Cashflow per Share
- 49.21
- Free CashFlow per Share
- -51.7
- Capex to Operating CashFlow
- 2.05
- Capex to Revenue
- 0.28
- Capex to Depreciation
- 2.46
- Return on Invested Capital
- 0
- Return on Tangible Assets
- 0
- Days Sales Outstanding
- 62.9
- Days Payables Outstanding
- 33.16
- Days of Inventory on Hand
- 261.22
- Receivables Turnover
- 5.8
- Payables Turnover
- 11.01
- Inventory Turnover
- 1.4
- Capex per Share
- 100.92
Balance Sheet
- Cash per Share
- 315,32
- Book Value per Share
- 926,10
- Tangible Book Value per Share
- 870.01
- Shareholders Equity per Share
- 923.5
- Interest Debt per Share
- 0.19
- Debt to Equity
- 0
- Debt to Assets
- 0
- Net Debt to EBITDA
- -6.27
- Current Ratio
- 7.81
- Tangible Asset Value
- 104,76 Bil.
- Net Current Asset Value
- 50,78 Bil.
- Invested Capital
- 110028000000
- Working Capital
- 53,20 Bil.
- Intangibles to Total Assets
- 0.06
- Average Receivables
- 9,33 Bil.
- Average Payables
- 1,59 Bil.
- Average Inventory
- 12385000000
- Debt to Market Cap
- 0
Dividends
Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.
| Year | Dividends | Growth |
|---|---|---|
| 2012 | 1 | |
| 2013 | 1 | 0% |
| 2014 | 1 | 0% |
| 2015 | 2 | 0% |
| 2016 | 2 | 0% |
| 2017 | 4 | 75% |
| 2018 | 5 | 0% |
| 2019 | 7 | 42.86% |
| 2020 | 8 | 12.5% |
| 2021 | 9 | 11.11% |
| 2022 | 30 | 70% |
| 2023 | 42 | 28.57% |
| 2024 | 17 | -147.06% |
| 2025 | 0 | 0% |
Takara Bio Inc. Profile
About Takara Bio Inc.
Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops research reagents and scientific instruments; and provides contract development and manufacturing organization (CDMO) services for academic and corporate life sciences research and development. The company's CDMO services include contract service for developing regenerative medicine products; related services, such as quality and safety testing, and cell banking; and contract services for supporting genetic analysis and testing comprising human genome sequence analysis, analysis of cancerrelated genes, and intestinal flora analysis, as well as support services for genetic engineering research, such as genome editing using the latest technologies and equipment. It also engages in the development and commercialization of various gene therapies, including oncolytic virus utilizing Canerpaturev, which is an attenuated strain of the herpes simplex virus type 1 that exhibits antitumor activity upon local injection into a tumor due to tumor lysis; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of synovial sarcoma; and CD19 chimeric antigen receptors that is in Phase I/II clinical trial for the treatment of adult acute lymphoblastic leukemia. Additionally, the company offers RetroNectin for gene therapy. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.
- CEO
- Mr. Koichi Nakao
- Employee
- 1.838
- Address
-
7-4-38 Nojihigashi
Kusatsu, 525-0058
Takara Bio Inc. Executives & BODs
| # | Name | Age |
|---|---|---|
| 1 |
Mr. Katsuhiko Kusakabe CMCO, Senior Executive Officer & Director |
70 |
| 2 |
Mr. Koichi Nakao Chief Executive Officer, President & Representative Director |
70 |
| 3 |
Mr. Tsuyoshi Miyamura Senior Managing Director & Director |
70 |
| 4 |
Takuya Kakemi Executive Officer, Deputy GM of Corporate Headquarters & GM of Public Relations and IR Department |
70 |
| 5 |
Akira Kodera Managing Executive Officer & Head of Sales Division |
70 |
| 6 |
Noritaka Nishiwaki Executive Officer, Deputy GM of Corporate Headquarters & GM of Human Resources Department |
70 |
| 7 |
Kyoko Nakajima Managing Executive Officer & Head of SCM Division |
70 |
| 8 |
Mr. Andrew Farmer Ph.d. Head of Research and Development |
70 |
| 9 |
Mr. Junichi Mineno Ph.D. Vice President, Executive Officer & Director |
70 |
| 10 |
Dr. Yoh Hamaoka Ph.D. Chief Financial Officer, Senior Executive Officer & Director |
70 |
Takara Bio Inc. Competitors
